Development of a novel Fc fusion protein dual glucagon‐like peptide‐1 and gastric inhibitory polypeptide receptor agonists

To develop and investigate an imbalanced dual gastric inhibitory polypeptide receptor (GIPR)/glucagon‐like peptide‐1 receptor (GLP‐1 R) agonist with Fc fusion protein structure.

[1]  G. Rutter,et al.  In vivo and in vitro characterization of GL0034, a novel long‐acting glucagon‐like peptide‐1 receptor agonist , 2022, Diabetes, obesity & metabolism.

[2]  L. Aronne,et al.  Tirzepatide Once Weekly for the Treatment of Obesity. , 2022, The New England journal of medicine.

[3]  M. Rosenkilde,et al.  GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation , 2022, Peptides.

[4]  H. Grill,et al.  GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models , 2021, Diabetes.

[5]  T. Borner,et al.  The Role of GIP in the Regulation of GLP-1 Satiety and Nausea , 2021, Diabetes.

[6]  J. Rosenstock,et al.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. , 2021, The New England journal of medicine.

[7]  J. Harrold,et al.  GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys , 2021, Cell reports. Medicine.

[8]  Chiadi E. Ndumele,et al.  Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2021, Circulation.

[9]  D. D’Alessio,et al.  GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells , 2021, Science Advances.

[10]  A. Feuchtinger,et al.  The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling , 2021, Cell metabolism.

[11]  K. Duffin,et al.  Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes , 2020, The Journal of clinical endocrinology and metabolism.

[12]  M. Nauck,et al.  GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art , 2020, Molecular metabolism.

[13]  Yuan Cheng,et al.  Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism , 2020, Nature Communications.

[14]  J. Holst,et al.  Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist , 2020, JCI insight.

[15]  J. Holst,et al.  Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study , 2019, Diabetologia.

[16]  M. Tschöp,et al.  Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism , 2018, Molecular metabolism.

[17]  M. Tschöp,et al.  Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases , 2018, Nature Reviews Endocrinology.

[18]  R. Gimeno,et al.  LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept , 2018, Molecular metabolism.

[19]  G. Rutter,et al.  Targeting GLP-1 receptor trafficking to improve agonist efficacy , 2018, Nature Communications.

[20]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[21]  J. Daugaard,et al.  A novel GIP analogue, ZP4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents , 2018, Diabetes, obesity & metabolism.

[22]  H. Choi,et al.  Central administration of GLP-1 and GIP decreases feeding in mice. , 2017, Biochemical and biophysical research communications.

[23]  M. Tschöp,et al.  The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. , 2017, Cell metabolism.

[24]  V. Beral,et al.  Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents , 2016, The Lancet.

[25]  J. Holst,et al.  Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors , 2015, British journal of pharmacology.

[26]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[27]  D. Drucker,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[28]  T. Vilsbøll,et al.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes , 2009, Diabetologia.

[29]  N. Irwin,et al.  (Pro3)GIP[mPEG]: novel, long‐acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity‐diabetes (diabesity) therapy , 2008, British journal of pharmacology.

[30]  J. Holst,et al.  GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. , 2007, American journal of physiology. Endocrinology and metabolism.

[31]  C. Mantzoros,et al.  Pharmacotherapy of type 2 diabetes: An update. , 2018, Metabolism: clinical and experimental.